Breed s Hill Capital LLC Purchases 150 Shares of Johnson & Johnson $JNJ

Breed s Hill Capital LLC boosted its position in Johnson & Johnson (NYSE:JNJ) by 4.4% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,530 shares of the company’s stock after acquiring an additional 150 shares during the period. Breed s Hill Capital LLC’s holdings in Johnson & Johnson were worth $585,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Highline Wealth Partners LLC grew its holdings in Johnson & Johnson by 51.8% in the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock worth $42,000 after acquiring an additional 86 shares during the last quarter. Stone House Investment Management LLC bought a new stake in shares of Johnson & Johnson during the 1st quarter valued at about $47,000. von Borstel & Associates Inc. bought a new stake in shares of Johnson & Johnson during the 1st quarter valued at about $49,000. Capital A Wealth Management LLC bought a new stake in shares of Johnson & Johnson during the 4th quarter valued at about $50,000. Finally, Harvest Fund Management Co. Ltd bought a new stake in shares of Johnson & Johnson during the 1st quarter valued at about $52,000. Institutional investors own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on JNJ shares. Wall Street Zen lowered shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 18th. Barclays lifted their target price on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a research note on Thursday, July 17th. Leerink Partners lowered shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and cut their target price for the company from $169.00 to $153.00 in a research note on Tuesday, May 13th. Benchmark raised shares of Johnson & Johnson to a “strong-buy” rating in a research note on Thursday, April 24th. Finally, Royal Bank Of Canada lifted their target price on shares of Johnson & Johnson from $181.00 to $185.00 and gave the company an “outperform” rating in a research note on Thursday, July 17th. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $174.50.

Johnson & Johnson Trading Up 0.8%

NYSE:JNJ opened at $177.7060 on Wednesday. Johnson & Johnson has a one year low of $140.68 and a one year high of $178.18. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The company’s 50-day simple moving average is $162.13 and its 200 day simple moving average is $158.73. The firm has a market capitalization of $427.98 billion, a P/E ratio of 19.01, a PEG ratio of 2.24 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same quarter in the previous year, the firm posted $2.82 earnings per share. Johnson & Johnson’s quarterly revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.9%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio is currently 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.